Sirolimus protein-bound particles is approved for malignant perivascular epithelioid cell tumor

Jan 2022: For adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumours, the Food and Drug Administration licenced sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro, Aadi Bioscience, Inc.) (PEComa).

Efficacy was tested in 31 patients with locally advanced unresectable or metastatic malignant PEComa in AMPECT (NCT02494570), a multicenter, single-arm clinical study. On days 1 and 8 of each 21-day cycle, patients received 100 mg/m2 sirolimus protein-bound particles until disease progression or intolerable toxicity.

Overall response rate (ORR) and duration of response (DOR) were the key efficacy outcome measures, as determined by a blinded independent central review using RECIST v.1.1. The ORR was 39 percent (95 percent CI: 22 percent, 58 percent), with two patients responding completely. The median DOR was not met (95 percent CI: 6.5 months, not estimable). 67 percent of respondents had a response that lasted more than 12 months, and 58 percent had a response that lasted more than 24 months.

Stomatitis, weariness, rash, infection, nausea, edoema, diarrhoea, musculoskeletal discomfort, decreased weight, decreased appetite, cough, vomiting, and dysgeusia were the most prevalent side events (30 percent). Decreased lymphocytes, increased glucose, decreased potassium, decreased phosphate, decreased haemoglobin, and elevated lipase were the most prevalent grade 3 to 4 laboratory abnormalities (6%).

Until disease progression or intolerable toxicity, the recommended dosage is 100 mg/m2 given as an IV infusion over 30 minutes on days 1 and 8 of each 21-day cycle.

Click this link for full prescribing information for Fyarro.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Gaucher’s Disease in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Wilson’s Disease in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Phenylketonuria in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Best Cancer Hospitals in China 2025